230 related articles for article (PubMed ID: 22188362)
1. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.
Hung CC; Chang WL; Ho JL; Tai JJ; Hsieh TJ; Huang HC; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Jan; 13(2):159-69. PubMed ID: 22188362
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.
Daci A; Beretta G; Vllasaliu D; Shala A; Govori V; Norata GD; Krasniqi S
PLoS One; 2015; 10(11):e0142408. PubMed ID: 26555147
[TBL] [Abstract][Full Text] [Related]
3. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.
Ma CL; Jiao Z; Wu XY; Hong Z; Wu ZY; Zhong MK
Pharmacogenomics; 2015; 16(13):1499-512. PubMed ID: 26314341
[TBL] [Abstract][Full Text] [Related]
4. SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy.
Ma CL; Wu XY; Jiao Z; Hong Z; Wu ZY; Zhong MK
Pharmacogenomics; 2015; 16(4):347-60. PubMed ID: 25823783
[TBL] [Abstract][Full Text] [Related]
5. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy.
Ma CL; Wu XY; Zheng J; Wu ZY; Hong Z; Zhong MK
Pharmacogenomics; 2014 Jul; 15(10):1323-36. PubMed ID: 25155934
[TBL] [Abstract][Full Text] [Related]
6. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Yun W; Zhang F; Hu C; Luo X; Xue P; Wang J; Ge Y; Meng H; Guo Y
Epilepsy Res; 2013 Dec; 107(3):231-7. PubMed ID: 24125961
[TBL] [Abstract][Full Text] [Related]
7. Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
He XJ; Jian LY; He XL; Tang M; Wu Y; Xu YY; Sun XJ; Zhao LM
Epilepsia; 2014 Aug; 55(8):1301-6. PubMed ID: 24861996
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients.
Zhang ML; Chen XL; Bai ZF; Zhao X; Li WX; Wang XY; Zhang H; Chen XF; Zhang SQ; Tang JF; Xiao XH; Zhao YL
Gene; 2021 Dec; 805():145907. PubMed ID: 34411648
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of microsomal epoxide hydrolase and UDP-glucuronosyltransferase (UGT) and its effects on plasma carbamazepine levels and metabolic ratio in persons with epilepsy of South India: A cross-sectional genetic association study.
Venkatraman S; Ramasamy K; Nair PP
Indian J Pharmacol; 2023; 55(3):149-154. PubMed ID: 37555408
[TBL] [Abstract][Full Text] [Related]
10. Influence of
Venkatraman S; Ramasamy K; Nair PP; Rajendran P
Drug Metab Pers Ther; 2023 Jun; 38(2):191-197. PubMed ID: 36853909
[TBL] [Abstract][Full Text] [Related]
11. Association of genetic variants in six candidate genes with valproic acid therapy optimization.
Hung CC; Ho JL; Chang WL; Tai JJ; Hsieh TJ; Hsieh YW; Liou HH
Pharmacogenomics; 2011 Aug; 12(8):1107-17. PubMed ID: 21806385
[TBL] [Abstract][Full Text] [Related]
12. Relevance of
Fricke-Galindo I; Jung-Cook H; Martínez-Juárez IE; Monroy-Jaramillo N; Ortega-Vázquez A; Rojas-Tomé IS; Dorado P; Peñas-Lledó E; Llerena A; López-López M
Pharmacogenomics; 2021 Oct; 22(15):983-996. PubMed ID: 34612084
[No Abstract] [Full Text] [Related]
13. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.
Chbili C; Fathallah N; Laouani A; Nouira M; Hassine A; Ben Amor S; Ben Ammou S; Ben Salem C; Saguem S
J Neurogenet; 2016 Mar; 30(1):16-21. PubMed ID: 27276192
[TBL] [Abstract][Full Text] [Related]
14. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
Puranik YG; Birnbaum AK; Marino SE; Ahmed G; Cloyd JC; Remmel RP; Leppik IE; Lamba JK
Pharmacogenomics; 2013 Jan; 14(1):35-45. PubMed ID: 23252947
[TBL] [Abstract][Full Text] [Related]
15. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.
Zhu X; Yun W; Sun X; Qiu F; Zhao L; Guo Y
Pharmacogenomics; 2014; 15(15):1867-79. PubMed ID: 25495409
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
[TBL] [Abstract][Full Text] [Related]
18. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
Seo T; Ishitsu T; Ueda N; Nakada N; Yurube K; Ueda K; Nakagawa K
Pharmacogenomics; 2006 Jun; 7(4):551-61. PubMed ID: 16753003
[TBL] [Abstract][Full Text] [Related]
20. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Sánchez MB; Herranz JL; Leno C; Arteaga R; Oterino A; Valdizán EM; Nicolás JM; Adín J; Armijo JA
Seizure; 2010 Mar; 19(2):93-101. PubMed ID: 20064729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
